Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RGX202 |
Synonyms | |
Therapy Description |
RGX202 is an SLC6A8 inhibitor that blocks the uptake of phosphocreatine, thereby potentially reducing ATP synthesis and resulting in the inhibition of tumor growth and metastasis (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 3504-3504). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RGX202 | RGX-202-01|RGX-202|RGX 202|Ompenaclid | RGX202 is an SLC6A8 inhibitor that blocks the uptake of phosphocreatine, thereby potentially reducing ATP synthesis and resulting in the inhibition of tumor growth and metastasis (J Clin Oncol 38, no. 15_suppl (May 20, 2020) 3504-3504). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03597581 | Phase I | RGX202 Fluorouracil + Irinotecan + Leucovorin + RGX202 Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + RGX202 | A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer | Completed | USA | 0 |